Veeva Systems Inc ((VEEV)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: The study titled ‘Nutrition, Microbiome and Bone Health During Early Life Related to Health’ aims to explore the impact of nutrition on microbiome and bone development in children from birth to three years. Conducted by Société des Produits Nestlé and collaborators including Veeva Systems, the study seeks to establish reference trajectories for gut microbiome maturation and bone development, assessing how early life nutrition influences these factors.
Intervention/Treatment: This observational study does not involve any specific interventions. Instead, it follows two groups of healthy infants and their mothers to gather data on natural developmental trajectories.
Study Design: The study employs a cohort observational model with a prospective time perspective. It involves collecting fecal, urine, and breastmilk samples to analyze microbiome and bone health without any intervention or treatment allocation.
Study Timeline: The study began on September 3, 2021, with a primary completion date yet to be announced. The latest update was submitted on June 30, 2025, indicating ongoing data collection and analysis.
Market Implications: This study update could positively influence Veeva Systems’ stock performance by showcasing its involvement in significant health research. As the study progresses, investor sentiment may improve, especially if results highlight novel insights into nutrition’s role in early development, potentially setting Veeva apart from competitors in the health tech industry.
The study is ongoing, with further details available on the ClinicalTrials portal.